Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
49.1M
-
Shares change
-
+7.46M
-
Total reported value, excl. options
-
$460M
-
Value change
-
+$67.9M
-
Put/Call ratio
-
1.6
-
Number of buys
-
61
-
Number of sells
-
-49
-
Price
-
$9.37
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q4 2018
136 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q4 2018.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.1M shares
of 126M outstanding shares and own 38.79% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (8.22M shares), Consonance Capital Management LP (4.81M shares), Palo Alto Investors LP (4.69M shares), BlackRock Inc. (4.26M shares), Ridgeback Capital Investments L.P. (3.95M shares), STATE STREET CORP (2.52M shares), FRANKLIN RESOURCES INC (1.8M shares), Candriam Luxembourg S.C.A. (1.79M shares), Vanguard Group Inc (1.73M shares), and Point72 Asset Management, L.P. (1.54M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.